Related Experiment Video
Updated: Aug 17, 2026
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
[Inhibitory effect of endostatin mediated by lipofectin on transplanted ovarian cancer]
Zeng-tao Wei1, Xiao-yan Wang, Jian-chun Dong
1Department of Obstetrics and Gynecology, Medical College, Shandong University, Jinan 250012, China.
Objective:
To study the inhibitory effect of endostatin mediated by lipofectin on transplanted ovarian cancer in nude mice.
Methods:
Constructed recombinant vector pVAX1-sEn expressing human endostatin protein was transfected into ovarian cancer cell line 3AO by lipofectin. mRNA of endostatin was detected by RT-PCR. The expression of endostatin in supernatants was detected by enzyme-linked immunosorbent assay (ELISA). The inhibitory effect of pVAX1-sEn on endothelial cell line ECV-204 was detected by methyl thiazolyl tetrazolium (MTT). By use of lipofectin mediated pVAX1-sEn for intratumor injection, the inhibitory effect on growth of ovarian cancer was observed.
Results:
The result of RT-PCR showed there was a specific band at 610 bp. The expression quantity of endostatin in transfected cell supernatant was (201 +/- 8) ng/ml by ELISA. MTT showed pVAX1-sEn transfected cell supernatant could effectively inhibit the growth of ECV-204, the highest inhibitory ratio was 42%. The tumor volumes in pVAX1-sEn treatment group was (0.85 +/- 0.18) cm(3), significantly smaller than that in normal saline control group (1.90 +/- 0.28) cm(3) and pVAX1 control group (1.78 +/- 0.32) cm(3) (P < 0.05). HE stain in tumor tissue showed that there were obvious necrosis cells in the pVAX1-sEn treatment group, but there were flourishly growing tumor cells in pVAX1 and normal saline control groups.
Conclusion:
pVAX1-sEn mediated by lipofectin can effectively inhibit the growth of ovarian cancer.
Insights
Lipofectin-mediated delivery of endostatin effectively inhibits ovarian cancer growth in mice. This approach demonstrated significant tumor reduction and induced necrosis, offering a promising therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Context:
- Ovarian cancer remains a significant health challenge with limited effective treatments.
- Endostatin is a potent anti-angiogenic factor with therapeutic potential.
- Gene delivery systems are crucial for targeted therapeutic agent delivery.
Purpose:
- To evaluate the efficacy of lipofectin-mediated endostatin delivery for inhibiting transplanted ovarian cancer in nude mice.
- To assess the anti-tumorigenic effects of the recombinant vector pVAX1-sEn expressing human endostatin.
Summary:
- Human endostatin was expressed in the ovarian cancer cell line 3AO using the recombinant vector pVAX1-sEn and lipofectin.
- RT-PCR and ELISA confirmed endostatin expression.
- In vitro studies showed significant inhibition of endothelial cell growth (42%).
- In vivo studies demonstrated a marked reduction in tumor volume (0.85 cm³ vs. 1.90 cm³ in controls) and induced tumor cell necrosis.
Impact:
- Lipofectin-mediated pVAX1-sEn delivery shows significant potential as a therapeutic strategy for ovarian cancer.
- This approach offers a targeted method to inhibit tumor growth and angiogenesis.
- Further research may lead to novel gene therapy applications in gynecological oncology.
